Literature DB >> 15546206

Converting weak binders into infinite binders.

Todd M Corneillie1, Paul A Whetstone, Kelvin C Lee, Jeremy P Wong, Claude F Meares.   

Abstract

Monoclonal antibody 2D12.5 binds DOTA chelates of all the rare earths with K(d) approximately 10(-)(8) M, making it useful for the capture of probe molecules with a variety of properties. To make 2D12.5 even more useful for biological applications, we have engineered a single cysteine residue at position 54 of the heavy chain, a site proximal to the protein's binding site, so that weakly electrophilic metal complexes of (S)-2-(4-acrylamidobenzyl)-DOTA (AABD) may bind and form permanent linkages. At 37 degrees C, pH 7.5, all of the rare earth-AABD complexes bind permanently to the 2D12.5 G54C mutant within 5 min, in yields that correlate with their relative binding affinities. Surprisingly, indium-AABD also binds permanently in >50% yield within 5 min, despite the fact that changing the metal to indium reduces the affinity approximately 100x; even copper-AABD, which has approximately 10 000x lower binding affinity than the rare earths, binds permanently in >70% yield within 2 h. However, acrylamido compounds with no measurable affinity do not bind permanently. The important practical implication is that the G54C mutant of 2D12.5 may be used for applications that include not only the rare earths, but also an unexpected range of other elements as well. This infinite binding system can exhibit selective and permanent attachment with a remarkable range of structurally related ligands, albeit at slower rates as affinities decrease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546206     DOI: 10.1021/bc049825e

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  8 in total

1.  New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation.

Authors:  Tolulope A Aweda; Vahid Eskandari; David L Kukis; David L Boucher; Bernadette V Marquez; Heather E Beck; Gregory S Mitchell; Simon R Cherry; Claude F Meares
Journal:  Bioconjug Chem       Date:  2011-07-22       Impact factor: 4.774

Review 2.  The chemistry of irreversible capture.

Authors:  Claude F Meares
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

3.  Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.

Authors:  Simone Krebs; Afruja Ahad; Lukas M Carter; Justin Eyquem; Christian Brand; Meghan Bell; Vladimir Ponomarev; Thomas Reiner; Claude F Meares; Stephen Gottschalk; Michel Sadelain; Steven M Larson; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2018-06-14       Impact factor: 10.057

Review 4.  Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.

Authors:  Candice Ashmore-Harris; Madeleine Iafrate; Adeel Saleem; Gilbert O Fruhwirth
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454

5.  Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.

Authors:  Kelly Davis Orcutt; Adrian L Slusarczyk; Maryelise Cieslewicz; Benjamin Ruiz-Yi; Kumar R Bhushan; John V Frangioni; K Dane Wittrup
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

6.  Cysteinylated protein as reactive disulfide: an alternative route to affinity labeling.

Authors:  Zheng Miao; Mark R McCoy; Diment D Singh; Brianda Barrios; Oliver L Hsu; Sarah M Cheal; Claude F Meares
Journal:  Bioconjug Chem       Date:  2007-12-07       Impact factor: 4.774

7.  Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.

Authors:  Sarah M Cheal; Hong Xu; Hong-fen Guo; Pat B Zanzonico; Steven M Larson; Nai-Kong Cheung
Journal:  Mol Cancer Ther       Date:  2014-06-18       Impact factor: 6.261

8.  Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.

Authors:  Fuqiang Shao; Yu Long; Hao Ji; Dawei Jiang; Ping Lei; Xiaoli Lan
Journal:  Theranostics       Date:  2021-05-03       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.